nach oben

Obesity Surgery

Erschienen in:

22.04.2020 | Review

Revisiting the Ghrelin Changes Following Bariatric and Metabolic Surgery

verfasst von: Carlota Tuero, Victor Valenti, Fernando Rotellar, Manuel F. Landecho, Javier A. Cienfuegos, Gema Frühbeck

Erschienen in: Obesity Surgery | Ausgabe 7/2020

Einloggen, um Zugang zu erhalten

Abstract

Since the description of ghrelin in 1999, several studies have dug into the effects of this hormone and its relationship with bariatric surgery. While some aspects are still unresolved, a clear connection between ghrelin and the changes after metabolic surgery have been established. Besides weight loss, a significant amelioration in obesity-related comorbidities following surgery has also been reported. These changes in patients occur in the early postoperative period, before the weight loss appears, so that amelioration may be mainly due to hormonal changes. The purpose of this review is to go through the current body of knowledge of ghrelin’s physiology, as well as to update and clarify the changes that take place in ghrelin concentrations following bariatric/metabolic surgery together with their potential consolidation to outcomes.

Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature [Internet]. 1999 [cited 2017 Nov 12];402:656–660. Available from: https://doi.org/10.1038/45230

Müller TD, Nogueiras R, Andermann ML, Andrews ZB, Anker SD, Argente J, et al. Ghrelin. Mol Metab [Internet]. 2015 [cited 2017 Nov 1];4:437–60. Available from: http://linkinghub.elsevier.com/retrieve/pii/S2212877815000605

Delporte C, Christine. Structure and physiological actions of ghrelin. Scientifica (Cairo) [Internet]. 2013;2013:518909. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24381790%5Cnhttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC3863518

Pradhan G, Samson SL, Sun Y. Ghrelin: much more than a hunger hormone. Curr Opin Clin Nutr Metab Care [Internet]. 2013;16:619–24. Available from: https://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00075197-201311000-00003%5Cn, https://www.ncbi.nlm.nih.gov/pubmed/24100676%5Cnhttps://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC4049314

Tschöp M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature [Internet]. 2000 [cited 2017 Oct 26];407:908–13. Available from: https://doi.org/10.1038/35038090

Gauna C, van de Zande B, van Kerkwijk A, Themmen APN, van der Lely AJ, Delhanty PJD. Unacylated ghrelin is not a functional antagonist but a full agonist of the type 1a growth hormone secretagogue receptor (GHS-R). Mol Cell Endocrinol [Internet]. 2007 [cited 2017 Nov 11];274:30–4. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17601657

Gnanapavan S, Kola B, Bustin SA, Morris DG, McGee P, Fairclough P, et al. The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J Clin Endocrinol Metab [Internet]. 2002 [cited 2017 Nov 12];87:2988–2988. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12050285

Monteleone P, Bencivenga R, Longobardi N, et al. Differential responses of circulating ghrelin to high- fat or high-carbohydrate meal in healthy women. J Clin Endocrinol Metab. 2003;88:5510–4.PubMed

Zhao T-J, Sakata I, Li RL, et al. Ghrelin secretion stimulated by β1-adrenergic receptors in cultured ghrelinoma cells and in fasted mice. PNAS. 2010;107:15868–73.PubMed

10.

Broglio F, Gottero C, Van Koetsveld P, Prodam F, Destefanis S, Benso A, et al. Acetylcholine regulates ghrelin secretion in humans. J Clin Endocrinol Metab [Internet]. 2004 [cited 2017 Dec 6];89:2429–33. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15126574

11.

Maja S, Engelstoft W-m P, Sakata I, et al. Seven transmembrane G protein-coupled receptor repertoire of gastric ghrelin cells. Mol Metab. 2013;2:376–92.

12.

Zigman JM, Bouret SG, Andrews ZB. Obesity impairs the action of the neuroendocrine ghrelin system. Trends Endocrinol Metab [Internet]. 2016 [cited 2017 Oct 26];27:54–63. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4814209/pdf/nihms769029.pdf

13.

Gutierrez JA, Solenberg PJ, Perkins DR, Willency JA, Knierman MD, Jin Z, et al. Ghrelin octanoylation mediated by an orphan lipid transferase. Proc Natl Acad Sci U S A [Internet]. 2008 [cited 2017 Nov 11];105:6320–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18443287

14.

Goebel-Stengel M, Hofmann T, Elbelt U, Teuffel P, Ahnis A, Kobelt P, et al. The ghrelin activating enzyme ghrelin-O-acyltransferase (GOAT) is present in human plasma and expressed dependent on body mass index. Peptides [Internet]. 2013 [cited 2017 Nov 11];43:13–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23454172

15.

Sato T, Ida T, Nakamura Y, Shiimura Y, Kangawa K, Kojima M. Physiological roles of ghrelin on obesity. Obes Res Clin Pract [Internet]. 2014 [cited 2017 Nov 1];8:e405–13. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1871403X1300197X

16.

Satou M, Sugimoto H. The study of ghrelin deacylation enzymes. Methods Enzymol [Internet]. 2012 [cited 2017 Nov 11]. p. 165–79. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22975053

17.

Barnett BP, Hwang Y, Taylor MS, Kirchner H, Pfluger PT, Bernard V, et al. Glucose and weight control in mice with a designed ghrelin O-acyltransferase inhibitor. Science (80- ) [Internet]. 2010 [cited 2017 Nov 11];330:1689–92. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21097901

18.

Khatib MN, Gaidhane S, Gaidhane AM, et al. Ghrelin O acyl transferase (GOAT) as a novel metabolic regulatory enzyme. J Clin Diagnostic Res. 2015;9:LE01–5.

19.

Gargantini E, Grande C, Trovato L, Ghigo E, Granata R. The role of obestatin in glucose and lipid metabolism. Horm Metab Res [Internet]. 2013 [cited 2017 Oct 25];45:1002–8. Available from: https://doi.org/10.1055/s-0033-1351325

20.

Lippl F, Erdmann J, Lichter N, Tholl S, Wagenpfeil S, Adam O, et al. Relation of plasma obestatin levels to bmi, gender, age and insulin. Horm Metab Res [Internet]. 2008 [cited 2017 Nov 7];40:806–12. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18622896

21.

Zhang J V, Ren P-G, Avsian-Kretchmer O, Luo C-W, Rauch R, Klein C, et al. Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin’s effects on food intake. Science [Internet]. 2005 [cited 2017 Oct 25];310:996–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16284174

22.

Gourcerol, G., Taché Y. Obestatin a ghrelin-associated peptide that does not hold its promise to suppress food intake and motility. Neurogastroenterol Motil [Internet]. 2007 [cited 2017 Nov 5];19:161–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17300284

23.

Granata R, Settanni F, Gallo D, Trovato L, Biancone L, Cantaluppi V, et al. Obestatin promotes survival of pancreatic -cells and human islets and induces expression of genes involved in the regulation of -cell mass and function. Diabetes [Internet]. 2008 [cited 2018 Mar 4];57:967–79. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18162507

24.

Dimitriadis GK, Randeva MS, Miras AD. Potential hormone mechanisms of bariatric surgery. Curr Obes Rep. 2017:253–65. Available from:. https://doi.org/10.1007/s13679-017-0276-5.

25.

Huda MSB, Durham BH, Wong SP, Deepak D, Kerrigan D, McCulloch P, et al. Plasma obestatin levels are lower in obese and post-gastrectomy subjects, but do not change in response to a meal. Int J Obes [Internet]. 2008 [cited 2017 Nov 7];32:129–35. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17667911

26.

Martins C, Kjelstrup L, Mostad IL, et al. Impact of sustained weight loss achieved through Roux-en-Y gastric bypass or a lifestyle intervention on ghrelin, obestatin, and ghrelin/obestatin ratio in morbidly obese patients. Obes Surg. 2011;21:751–8.PubMed

27.

Roth CL, Reinehr T, Schernthaner G-H, Kopp H-P, Kriwanek S, Schernthaner G. Ghrelin and obestatin levels in severely obese women before and after weight loss after Roux-en-Y gastric bypass surgery. Obes Surg [Internet]. 2009 [cited 2017 Nov 11];19:29–35. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18521699

28.

Lim CT, Kola B, Korbonits M. The ghrelin/GOAT/GHS-R system and energy metabolism. Rev Endocr Metab Disord [Internet]. 2011 [cited 2017 Dec 11];12:173–86. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21340583

29.

Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BE, Weigle DS. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes [Internet]. 2001 [cited 2017 Dec 11];50:1714–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11473029

30.

Callahan HS, Cummings DE, Pepe MS, Breen PA, Matthys CC, Weigle DS. Postprandial Suppression of plasma ghrelin level is proportional to ingested caloric load but does not predict intermeal interval in humans. J Clin Endocrinol Metab [Internet]. 2004 [cited 2017 Dec 11];89:1319–24. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15001628

31.

Méquinion M, Langlet F, Zgheib S, Dickson S, Dehouck B, Chauveau C, et al. Ghrelin: central and peripheral implications in anorexia nervosa. Front Endocrinol (Lausanne) [Internet]. 2013 [cited 2018 Mar 3];4:15. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23549309

32.

Tschöp M, Weyer C, Tataranni PA, Devanarayan V, Ravussin E, Heiman ML. Circulating ghrelin levels are decreased in human obesity. Diabetes [Internet]. 2001 [cited 2017 Dec 11];50:707–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11289032

33.

English PJ, Ghatei MA, Malik IA, Bloom SR, Wilding JPH. Food fails to suppress ghrelin levels in obese humans. J Clin Endocrinol Metab [Internet]. 2002 [cited 2017 Nov 1];87:2984–2984. Available from: https://doi.org/10.1210/jcem.87.6.8738

34.

Yang N, Liu X, Ding EL, Xu M, Wu S, Liu L, et al. Impaired ghrelin response after high-fat meals is associated with decreased satiety in obese and lean Chinese young adults. J Nutr [Internet]. 2009 [cited 2017 Nov 1];139:1286–91. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19458028

35.

Hooper LE, Foster-Schubert KE, Weigle DS, Sorensen B, Ulrich CM, McTiernan A. Frequent intentional weight loss is associated with higher ghrelin and lower glucose and androgen levels in postmenopausal women. Nutr Res [Internet]. 2010 [cited 2017 Nov 1];30:163–70. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20417876

36.

Rodríguez A, Gómez-Ambrosi J, Catalán V, Gil MJ, Becerril S, Sáinz N, et al. Acylated and desacyl ghrelin stimulate lipid accumulation in human visceral adipocytes. Int J Obes [Internet]. 2009 [cited 2017 Oct 26];33:541–52. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19238155

37.

Dardzińska JA, Małgorzewicz S, Kaska Ł, Proczko M, Stefaniak T, Stankiewicz M, et al. Fasting and postprandial acyl and desacyl ghrelin levels in obese and non-obese subjects. Endokrynol Pol [Internet]. 2014 [cited 2017 Nov 21];65:377–81. Available from: http://czasopisma.viamedica.pl/ep/article/view/39796

38.

Naznin F, Toshinai K, Waise TMZ, NamKoong C, Md Moin AS, Sakoda H, et al. Diet-induced obesity causes peripheral and central ghrelin resistance by promoting inflammation. J Endocrinol [Internet]. 2015 [cited 2017 Nov 1];226:81–92. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26016745

39.

Rhea EM, Salameh TS, Logsdon AF, et al. Blood-brain barriers in obesity. AAPS. 2017;19:921–30.

40.

Sumithran P, Prendergast LA, Delbridge E, Purcell K, Shulkes A, Kriketos A, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med [Internet]. 2011 [cited 2017 Nov 1];365:1597–604. Available from: https://doi.org/10.1056/NEJMoa1105816

41.

Cummings DE. Ghrelin and the short- and long-term regulation of appetite and body weight. Physiol Behav. 2006;89:71–84.PubMed

42.

Nymo S, Coutinho SR, Eknes PH, et al. Investigation of the long-term sustainability of changes in appetite after weight loss. Int J Obes. 2018;42:1489–99.

43.

Iepsen EW, Lundgren J, Holst JJ, et al. Successful weight loss maintenance includes long-term increased meal responses of GLP-1 and PYY. Eur J Endocrinol. 2016;174:775–84.PubMed

44.

Bohdjalian A, Langer FB, Shakeri-Leidenmühler S, Gfrerer L, Ludvik B, Zacherl J, et al. Sleeve gastrectomy as sole and definitive bariatric procedure: 5-year results for weight loss and ghrelin. Obes Surg [Internet]. 2010 [cited 2017 Dec 3];20:535–40. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20094819

45.

Xu HC, Pang YC, Chen JW, et al. Systematic review and meta-analysis of the change in ghrelin levels after Roux-en-Y gastric bypass. Obes Surg. 2019;29:1343–51.PubMed

46.

Broglio F, Arvat E, Benso A, Gottero C, Muccioli G, Papotti M, et al. Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans. J Clin Endocrinol Metab [Internet]. 2001 [cited 2017 Oct 31];86:5083–5083. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11600590

47.

Broglio F, Gottero C, Prodam F, Gauna C, Muccioli G, Papotti M, et al. Non-acylated ghrelin counteracts the metabolic but not the neuroendocrine response to acylated ghrelin in humans. J Clin Endocrinol Metab [Internet]. 2004 [cited 2017 Nov 13];89:3062–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15181099

48.

Tong J, Prigeon RL, Davis HW, et al. Ghrelin suppresses glucose-stimulated insulin secretion and deteriorates glucose tolerance in healthy humans. Diabetes. 2010;59:2145–51.PubMedPubMedCentral

49.

Mani BK, Shankar KZJ. Ghrelin’s relationship to blood glucose. Endocrinology. 2019;160:1247–61.PubMedPubMedCentral

50.

Sun Y, Asnicar M, Saha PK, et al. Ablation of ghrelin improves the diabetic but not obese phenotype of Ob/ob mice. Cell Metab. 2006;3:379–86.PubMed

51.

Tamboli RA, Antoun J, Sidani RM, et al. Metabolic responses to exogenous ghrelin in obesity and early after Roux-en-Y gastric bypass in humans. Diabetes Obes Metab. 2017;19:1267–75.PubMedPubMedCentral

52.

Zhao T-J, Liang G, Li RL, Xie X, Sleeman MW, Murphy AJ, et al. Ghrelin O-acyltransferase (GOAT) is essential for growth hormone-mediated survival of calorie-restricted mice. Proc Natl Acad Sci [Internet]. 2010 [cited 2017 Oct 31];107:7467–72. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20231469

53.

Al Massadi O, López M, Tschöp M, et al. Current understanding of the hypothalamic ghrelin pathways inducing appetite and adiposity. Trends Neurosci [Internet]. Elsevier Ltd. 2017;40:167–80. Available from:. https://doi.org/10.1016/j.tins.2016.12.003.CrossRef

54.

Theander-Carrillo C, Wiedmer P, Cettour-Rose P, et al. Ghrelin action in the brain controls adipocyte metabolism. J Clin Invest. 2006;116:1983–93.PubMedPubMedCentral

55.

Frühbeck G, Méndez-Giménez L, Fernández-Formoso JA, et al. Regulation of adipocyte lipolysis. Nutr Res. 2014;27:63–93.

56.

Miao H, Pan H, Wang L, et al. Ghrelin promotes proliferation and inhibits differentiation of 3T3-L1 and human primary preadipocytes. Front Physiol. 2019;10:1296.PubMedPubMedCentral

57.

Heppner KM, Piechowski CL, Müller A, Ottaway N, Sisley S, Smiley DL, et al. Both acyl and des-acyl ghrelin regulate adiposity and glucose metabolism via central nervous system ghrelin receptors. Diabetes [Internet]. American Diabetes Association; 2014 [cited 2017 Oct 26];63:122–31. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24062249

58.

Gómez-Ambrosi J, Catalán V, Rodríguez A, et al. Increased cardiometabolic risk factors and inflammation in adipose tissue in obese subjects classified as metabolically healthy. Diabetes Care. 2014;37:2813–21.PubMed

59.

Ezquerro S, Mocha F, Frühbeck G, et al. Ghrelin reduces TNF-α-induced human hepatocyte apoptosis, autophagy, and pyroptosis: role in obesity-associated NAFLD. J Clin Endocrinol Metab. 2019;104:21–37.PubMed

60.

Tokudome T, Kishimoto I, Miyazato M, Kangawa K. Ghrelin and the cardiovascular system. Front Horm Res [Internet]. 2014 [cited 2017 Oct 25];43:125–33. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24943303

61.

Nagaya N, Kojima M, Uematsu M, et al. Hemodynamic and hormonal effects of human ghrelin in healthy volunteers. Am J Physiol Regul Integr Comp Physiol [Internet]. 2001;280:R1483–7. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11294772

62.

Nagaya N, Moriya J, Yasumura Y, Uematsu M, Ono F, Shimizu W, et al. Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. Circulation [Internet]. 2004 [cited 2017 Oct 25];110:3674–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15569841

63.

Gaigai Zhang, Xinhua Yin, Yongfen Qi, Lakshmana Pendyala, Jack Chen, Dongming Hou and CT. Ghrelin and cardiovascular diseases. Curr Cardiol Rev 2010;6:62–70.

64.

Leonetti F, Silecchia G, Iacobellis G, Ribaudo MC, Zappaterreno A, Tiberti C, et al. Different plasma ghrelin levels after laparoscopic gastric bypass and adjustable gastric banding in morbid obese subjects. J Clin Endocrinol Metab [Internet]. 2003 [cited 2017 Dec 5];88:4227–31. Available from: https://doi.org/10.1210/jc.2003-030133

65.

Ram E, Vishne T, Diker D, et al. Impact of gastric banding on plasma ghrelin, growth hormone, cortisol, DHEA and DHEA-s levels. Obes Surg. 2005;15:1118–23.PubMed

66.

Shak JR, Roper J, Perez-Perez GI, et al. The effect of laparoscopic gastric banding surgery on plasma levels of appetite-control, insulinotropic, and digestive hormones. Obes Surg. 2004;18:1089–96.

67.

Langer FB, Reza Hoda MA, Bohdjalian A, Felberbauer FX, Zacherl J, Wenzl E, et al. Sleeve gastrectomy and gastric banding: effects on plasma ghrelin levels. Obes Surg [Internet]. 2005 [cited 2017 Dec 6];15:1024–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16105401

68.

Stoeckli R, Chanda R, Langer I, Keller U. Changes of body weight and plasma ghrelin levels after gastric banding and gastric bypass. Obes Res [Internet]. 2004 [cited 2017 Dec 3];12:346–50. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14981228

69.

Nijhuis J, van Dielen FMH, Buurman WA, Greve JWM. Ghrelin, Leptin and insulin levels after restrictive surgery: a 2-year follow-up study. Obes Surg [Internet]. 2004 [cited 2017 Dec 5];14:783–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15318982

70.

Hady HR, Dadan JGP. 100 obese patients after laparoscopic adjustable gastric banding – the influence on BMI, gherlin and insulin concentration, parameters of lipid balance and co-morbidities. Adv Med Sci. 2012;57:58–64.PubMed

71.

Mariani LM, Fusco A, Turriziani M, et al. Transient increase of plasma ghrelin after laparoscopic adjustable gastric banding in morbid obesity. Horm Metab Res. 2005;37:242–5.PubMed

72.

Hanusch-Enserer U, Cauza E, Georg Brabant AD, et al. Plasma ghrelin in obesity before and after weight loss after laparoscopical adjustable gastric banding. J Clin Endocrinol Metab. 2004;89:3352–8.PubMed

73.

Gelisgen R, Zengin K, Kocael A, et al. Effects of laparoscopic gastric band applications on plasma and fundic acylated ghrelin levels in morbidly obese patients. Obes Surg. 2012;22:299–305.PubMed

74.

Kruljac I, Mirošević G, Kirigin LS, et al. Changes in metabolic hormones after bariatric surgery and their predictive impact on weight loss. Clin Endocrinol. 2016;85:852–60.

75.

Schindler K, Prager G, Ballaban T, Kretschmer S, Riener R, Buranyi B, et al. Impact of laparoscopic adjustable gastric banding on plasma ghrelin, eating behaviour and body weight. Eur J Clin Invest [Internet]. 2004 [cited 2017 Dec 6];34:549–54. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15305889

76.

Frühbeck G, Rotellar F, Hernández-Lizoain JL, Gil MJ, Gómez-Ambrosi J, Salvador J, et al. Fasting plasma ghrelin concentrations 6 months after gastric bypass are not determined by weight loss or changes in insulinemia. Obes Surg [Internet]. 2004 [cited 2017 Dec 3];14:1208–15. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15527636

77.

Tsouristakis AI, Febres G, Mcmahon DJ, et al. Long-term modulation of appetitive hormones and sweet cravings after adjustable gastric banding and Roux-en-Y gastric bypass. Obes Surg. 2019;29(11):3698–705

78.

Cummings DE, Weigle DS, Frayo RS, Breen PA, Ma MK, Dellinger EP, et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med [Internet]. 2002 [cited 2017 Dec 3];346:1623–30. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12023994

79.

Hansen TK, Dall R, Hosoda H, Kojima M, Kangawa K, Christiansen JS, et al. Weight loss increases circulating levels of ghrelin in human obesity. Clin Endocrinol (Oxf) [Internet]. 2002 [cited 2017 Dec 3];56:203–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11874411

80.

Peterli R, Steinert RE, Woelnerhanssen B, Peters T, Christoffel-Courtin C, Gass M, et al. Metabolic and hormonal changes after laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy: a randomized, prospective trial. Obes Surg [Internet]. 2012 [cited 2017 Dec 3];22:740–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22354457

81.

Anderson B, Switzer NJ, Almamar A, Shi X, Birch DW, Karmali S. The Impact of laparoscopic sleeve gastrectomy on plasma ghrelin levels: a systematic review. Obes Surg [Internet]. 2013 [cited 2017 Dec 6];23:1476–80. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23794092

82.

Frühbeck G, Diez Caballero A, Gil MJ. Fundus functionality and ghrelin concentrations after bariatric surgery. N Engl J Med [Internet]. 2004 [cited 2018 Jul 19];350:308–9. Available from: https://doi.org/10.1056/NEJM200401153500323

83.

Frühbeck G, Diez-Caballero A, Gil MJ, Montero I, Gómez-Ambrosi J, Salvador J, et al. The decrease in plasma ghrelin concentrations following bariatric surgery depends on the functional integrity of the fundus. Obes Surg [Internet]. 2004 [cited 2017 Dec 3];14:606–12. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15186626

84.

Yousseif A, Emmanuel J, Karra E, Millet Q, Elkalaawy M, Jenkinson AD, et al. Differential effects of laparoscopic sleeve gastrectomy and laparoscopic gastric bypass on appetite, circulating acyl-ghrelin, peptide YY3-36 and active GLP-1 levels in non-diabetic humans. Obes Surg [Internet]. 2014 [cited 2017 Dec 4];24:241–52. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23996294

85.

Alamuddin N, Vetter ML, Ahima RS, Hesson L, Ritter S, Minnick A, et al. Changes in fasting and prandial gut and adiposity hormones following vertical sleeve gastrectomy or Roux-en-Y-gastric bypass: an 18-month prospective study. Obes Surg [Internet]. 2017 [cited 2017 Dec 3];27:1563–72. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28004304

86.

Karamanakos SN, Vagenas K, Kalfarentzos F, Alexandrides TK. Weight loss, appetite suppression, and changes in fasting and postprandial ghrelin and peptide-YY levels after Roux-en-Y gastric bypass and sleeve gastrectomy. Ann Surg [Internet]. 2008 [cited 2017 Dec 4];247:401–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18376181

87.

Ramón JM, Salvans S, Crous X, Puig S, Goday A, Benaiges D, et al. Effect of Roux-en-Y gastric bypass vs sleeve gastrectomy on glucose and gut hormones: a prospective randomised trial. J Gastrointest Surg [Internet]. 2012 [cited 2017 Dec 4];16:1116–22. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22402955

88.

Dimitriadis E, Daskalakis M, Kampa M, Peppe A, Papadakis JA, Melissas J. Alterations in gut hormones after laparoscopic sleeve gastrectomy. Ann Surg [Internet]. 2013 [cited 2017 Dec 4];257:647–54. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23108120

89.

Melissas J, Leventi A, Klinaki I, Perisinakis K, Koukouraki S, de Bree E, et al. Alterations of global gastrointestinal motility after sleeve gastrectomy. Ann Surg [Internet]. 2013 [cited 2017 Dec 5];258:976–82. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23160151

90.

Braghetto I, Davanzo C, Korn O, Csendes A, Valladares H, Herrera E, et al. Scintigraphic evaluation of gastric emptying in obese patients submitted to sleeve gastrectomy compared to normal subjects. Obes Surg [Internet]. 2009 [cited 2017 Dec 5];19:1515–21. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19714384

91.

Baumann T, Kuesters S, Grueneberger J, Marjanovic G, Zimmermann L, Schaefer A-O, et al. Time-resolved MRI after ingestion of liquids reveals motility changes after laparoscopic sleeve gastrectomy--preliminary results. Obes Surg [Internet]. 2011 [cited 2017 Dec 6];21:95–101. Available from: https://doi.org/10.1007/s11695-010-0317-6

92.

Frühbeck G. Bariatric and metabolic surgery: a shift in eligibility and success criteria. Nat Rev Endocrinol [Internet]. 2015 [cited 2018 Jul 19];11:465–77. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26055046

93.

Cummings DE, Shannon MH. Roles for ghrelin in the regulation of appetite and body weight. Arch Surg [Internet]. 2003 [cited 2017 Dec 3];138:389. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12686525

94.

Tymitz K, Engel A, McDonough S, Hendy MP, Kerlakian G. Changes in ghrelin levels following bariatric surgery: review of the literature. Obes Surg [Internet]. 2011 [cited 2017 Dec 4];21:125–30. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21104455

95.

Tritos NA, Mun E, Bertkau A, Grayson R, Maratos-Flier E, Goldfine A. Serum ghrelin levels in response to glucose load in obese subjects post-gastric bypass surgery. Obes Res [Internet]. 2003 [cited 2017 Dec 3];11:919–24. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12917494

96.

Cummings DE, Shannon MH. Ghrelin and gastric bypass: is there a hormonal contribution to surgical weight loss? J Clin Endocrinol Metab. 2003;88:2999–3002.PubMed

97.

Lin E, Gletsu N, Fugate K, McClusky D, Gu LH, Zhu J-L, et al. The effects of gastric surgery on systemic ghrelin levels in the morbidly obese. Arch Surg [Internet]. 2004 [cited 2017 Dec 3];139:780–4. Available from: https://doi.org/10.1001/archsurg.139.7.780

98.

Peterli R, Wölnerhanssen B, Peters T, Devaux N, Kern B, Christoffel-Courtin C, et al. Improvement in glucose metabolism after bariatric surgery: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy. Ann Surg [Internet]. 2009 [cited 2017 Dec 3];250:234–41. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19638921

99.

Morínigo R, Casamitjana R, Moizé V, Lacy AM, Delgado S, Gomis R, et al. Short-term effects of gastric bypass surgery on circulating ghrelin levels. Obes Res [Internet]. 2004 [cited 2017 Dec 5];12:1108–16. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15292475

100.

Tanya M, Halliday SP, Schoen JA, et al. Comparison of surgical versus diet-induced weight loss on appetite regulation and metabolic health outcomes. Physiol Rep. 2019;7:1–15.

101.

Korner J, Bessler M, Cirilo LJ, Conwell IM, Daud A, Restuccia NL, et al. Effects of Roux-en-Y gastric bypass surgery on fasting and postprandial concentrations of plasma ghrelin, peptide YY, and insulin. J Clin Endocrinol Metab [Internet]. 2005 [cited 2017 Dec 3];90:359–65. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15483088

102.

Holdstock C, Engström BE, Öhrvall M, Lind L, Sundbom M, Karlsson FA. Ghrelin and adipose tissue regulatory peptides: effect of gastric bypass surgery in obese humans. J Clin Endocrinol Metab [Internet]. 2003 [cited 2017 Dec 3];88:3177–83. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12843162

103.

Barazzoni R, Zanetti M, Nagliati C, Cattin MR, Ferreira C, Giuricin M, et al. Gastric bypass does not normalize obesity-related changes in ghrelin profile and leads to higher acylated ghrelin fraction. Obesity [Internet]. 2013 [cited 2017 Dec 3];21:718–22. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23712974

104.

Pérez-Romero N, Serra A, Granada ML, Rull M, Alastrué A, Navarro-Díaz M, et al. Effects of two variants of Roux-en-Y gastric bypass on metabolism behaviour: focus on plasma ghrelin concentrations over a 2-year follow-up. Obes Surg [Internet]. Springer-Verlag; 2010 [cited 2017 Dec 6];20:600–9. Available from: https://doi.org/10.1007/s11695-009-0035-0

105.

le Roux CW, Neary NM, Halsey TJ, Small CJ, Martinez-Isla AM, Ghatei MA, et al. Ghrelin does not stimulate food intake in patients with surgical procedures involving vagotomy. J Clin Endocrinol Metab [Internet]. 2005 [cited 2017 Dec 6];90:4521–4. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15914532

106.

Maier C, Schaller G, Buranyi B, Nowotny P, Geyer G, Wolzt M, et al. The cholinergic system controls ghrelin release and ghrelin-induced growth hormone release in humans. J Clin Endocrinol Metab [Internet]. 2004 [cited 2017 Dec 6];89:4729–33. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15356087

107.

Sundbom M, Holdstock C, Engström BE, Karlsson FA. Early changes in ghrelin following Roux-en-Y gastric bypass: influence of vagal nerve functionality? Obes Surg [Internet]. 2007 [cited 2017 Dec 3];17:304–10. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17546836

108.

Faraj M, Havel PJ, Lis SP, Blank D, Sniderman AD, Cianflone K. Plasma acylation-stimulating protein, adiponectin, leptin, and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab [Internet]. 2003 [cited 2017 Dec 3];88:1594–602. Available from: https://www.ncbi.nlm.nih.gov/pubmed/12679444

109.

Topart PA, Becouarn G. Revision and reversal after biliopancreatic diversion for excessive side effects or ineffective weight loss: a review of the current literature on indications and procedures. Surg Obes Relat Dis [Internet]. 2015 [cited 2017 Dec 6];11:965–72. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25726366

110.

Anderson B, Gill RS, De Gara CJ, Karmali S, Gagner M. Biliopancreatic diversion: the effectiveness of duodenal switch and its limitations. Gastroenterol Res Pract [Internet]. 2013 [cited 2017 Dec 6];8. Available from: https://doi.org/10.1155/2013/974762

111.

Garcia-Fuentes E, Garrido-Sanchez L, Garcia-Almeida JM, et al. Different effect of laparoscopic Roux-en-Y gastric bypass and open biliopancreatic diversion of Scopinaro on serum PYY and ghrelin levels. Obes Surg. 2008;18:1424–19.PubMed

112.

Marina Tsoli, Aikaterini Chronaiou, Ioannis Kehagias, Fotis Kalfarentzos TKA. Hormone changes and diabetes resolution after biliopancreatic diversion and laparoscopic sleeve gastrectomy: a comparative prospective study. Surg Obes Relat Dis 2013;9:667–678.

113.

Adami GF, Cordera R, Marinari G, Lamerini G, Andraghetti G, Scopinaro N. Plasma ghrelin concentratin in the short-term following biliopancreatic diversion. Obes Surg [Internet]. 2003 [cited 2017 Dec 3];13:889–92. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14738676

114.

Santiago-Fernández C, García-Serrano S, Tome M, et al. Ghrelin levels could be involved in the improvement of insulin resistance after bariatric surgery. Endocrinol Diabetes Nutr. 2017;64:355–62.PubMed

115.

García-Unzueta MT, Fernández-Santiago R, Domínguez-Díez A, Vazquez-Salví L, Fernández-Escalante JC, Amado JA. Fasting plasma ghrelin levels increase progressively after biliopancreatic diversion: one-year follow-up. Obes Surg [Internet]. 2005 [cited 2017 Dec 6];15:187–90. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15802059

116.

Adami GF, Cordera R, Andraghetti G, Camerini GB, Marinari GM, Scopinaro N. Changes in serum ghrelin concentration following biliopancreatic diversion for obesity. Obes Res [Internet]. 2004 [cited 2017 Dec 6];12:684–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15090637

117.

Kotidis E V, Koliakos G, Papavramidis TS, Papavramidis ST. The effect of biliopancreatic diversion with pylorus-preserving sleeve gastrectomy and duodenal switch on fasting serum ghrelin, leptin and adiponectin levels: is there a hormonal contribution to the weight-reducing effect of this procedure? Obes Surg [Internet]. 2006 [cited 2017 Dec 6];16:554–9. Available from: https://doi.org/10.1381/096089206776944940

118.

Liou J-M, Lin J-T, Lee W-J, et al. The serial changes of ghrelin and leptin levels and their relations to weight loss after laparoscopic minigastric bypass surgery. Obes Surg. 2008;18:84–9.PubMed

119.

Hafezi-Nejad N, Bailey CR, Gunn AJ, Weiss CR. Weight loss after left gastric artery embolization: a systematic review and meta-analysis. J Vasc Interv Radiol [Internet]. Elsevier; 2019 [cited 2019 Sep 15];0. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31515000

120.

Bai Z-B, Qin Y-L, Deng G, Zhao G-F, Zhong B-Y, Teng G-J. Bariatric embolization of the left gastric arteries for the treatment of obesity: 9-month data in 5 patients. Obes Surg [Internet]. 2017 [cited 2018 Mar 4]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/29063494

121.

Kipshidze N, Archvadze A, Bertog S, Leon MB, Sievert H. Endovascular bariatrics: first in humans study of gastric artery embolization for weight loss. JACC Cardiovasc Interv [Internet]. 2015 [cited 2018 Mar 4];8:1641–4. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26493259

122.

Manning S, Pucci A, Batterham RL. Roux-en-Y gastric bypass: effects on feeding behavior and underlying mechanisms. J Clin Invest [Internet]. 2015 [cited 2018 Mar 3];125:939–48. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25729850

123.

le Roux CW, Bueter M, Theis N, Werling M, Ashrafian H, Löwenstein C, et al. Gastric bypass reduces fat intake and preference. Am J Physiol Regul Integr Comp Physiol [Internet]. American Physiological Society; 2011 [cited 2017 Dec 6];301:R1057-66. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21734019

124.

Faulconbridge LF, Ruparel K, Loughead J, Allison KC, Hesson LA, Fabricatore AN, et al. Changes in neural responsivity to highly palatable foods following Roux-en-Y gastric bypass, sleeve gastrectomy, or weight stability: an fMRI study. Obesity [Internet]. 2016 [cited 2017 Dec 4];24:1054–60. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27112067

125.

Thomas JR, Marcus E. High and low fat food selection with reported frequency intolerance following Roux-en-Y gastric bypass. Obes Surg [Internet]. 2008 [cited 2017 Dec 6];18:282–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18214629

126.

Redman LM, Heilbronn LK, Martin CK, de Jonge L, Williamson DA, Delany JP, et al. Metabolic and behavioral compensations in response to caloric restriction: implications for the maintenance of weight loss. Wang C, editor. PLoS One [Internet]. 2009 [cited 2017 Dec 6];4:e4377. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19198647

127.

Zerrweck C, Zurita L, Álvarez G, Maydón HG, Sepúlveda EM, Campos F, et al. Taste and olfactory changes following laparoscopic gastric bypass and sleeve gastrectomy. Obes Surg [Internet]. 2016 [cited 2018 Mar 3];26:1296–302. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26475030

128.

Makaronidis JM, Neilson S, Cheung W-H, Tymoszuk U, Pucci A, Finer N, et al. Reported appetite, taste and smell changes following Roux-en-Y gastric bypass and sleeve gastrectomy: effect of gender, type 2 diabetes and relationship to post-operative weight loss. Appetite [Internet]. 2016 [cited 2018 Mar 3];107:93–105. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0195666316302987

129.

Stice E, Spoor S, Bohon C, Veldhuizen MG, Small DM. Relation of reward from food intake and anticipated food intake to obesity: a functional magnetic resonance imaging study. J Abnorm Psychol [Internet]. 2008 [cited 2017 Dec 6];117:924–35. Available from: https://doi.org/10.1037/a0013600

130.

Stoeckel LE, Weller RE, Cook EW, Twieg DB, Knowlton RC, Cox JE. Widespread reward-system activation in obese women in response to pictures of high-calorie foods. Neuroimage [Internet]. 2008 [cited 2017 Dec 6];41:636–47. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18413289

131.

Jerlhag E, Egecioglu E, Landgren S, Salome N, Heilig M, Moechars D, et al. Requirement of central ghrelin signaling for alcohol reward. Proc Natl Acad Sci [Internet]. 2009 [cited 2017 Dec 6];106:11318–23. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19564604

132.

Blackburn AN, Hajnal ALL. The gut in the brain: the effects of bariatric surgery on alcohol consumption. Addict Biol. 2017;22:1540–53.PubMed

133.

Azam H, Shahrestani S, Phan K. Alcohol use disorders before and after bariatric surgery: a systematic review and meta-analysis. Ann Transl Med. 2018;6:148.PubMedPubMedCentral

134.

Hajnal A, Zharikov A, Polston JE, et al. Alcohol reward is increased after Roux-en-Y gastric bypass in dietary obese rats with differential effects following ghrelin antagonism. PLoS One. 2012;7:e49121.PubMedPubMedCentral

135.

James E, Mitchell RC, de Zwaan M, et al. Possible risk factors of increased suicide following bariatric surgery. Obesity (Silver Spring). 2013;21:665–72.

136.

Farokhnia M, Faulkner ML, Piacentino D, et al. Ghrelin: from a gut hormone to a potential therapeutic target for alcohol use disorder. Physiol Behav. 2019;204:49–57.PubMed

137.

Wittekind DA, Kratzsch J, Mergl R, et al. Alcohol consumption is positively associated with fasting serum ghrelin in non-dependent adults: results from the population-based LIFE-adult-study. Psychoneuroendocrinology. 2018;97:143–8.PubMed

138.

Orellana ER, Jamis C, Horvath NHA. Effect of vertical sleeve gastrectomy on alcohol consumption and preferences in dietary obese rats and mice: a plausible role for altered ghrelin signaling. Brain Res Bull. 2018;138:26–36.PubMed

139.

Neovius M, Bruze G, Jacobson P, et al. Bariatric Surgery & Suicide: Results from two controlled matched cohort studies. Lancet Diabetes Endocrinol. 2018;6:197–207.PubMedPubMedCentral

140.

Spittal MJ, Frühbeck G. Bariatric surgery: many benefits, but emerging risks. Lancet Diabetes Endocrinol [Internet]. 2018 [cited 2018 Aug 10];6:161–3. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29329974

141.

Lutter M, Sakata I, Osborne-Lawrence S, et al. The orexigenic hormone ghrelin defends against depressive symptoms of chronic stress. Nat Neurosci. 2008;11:752–3.PubMedPubMedCentral

142.

Kluge M, Schüssler P, Dresler M, et al. Effects of ghrelin on psychopathology, sleep and secretion of cortisol and growth hormone in patients with major depression. J Psychiatr Res. 2011;45:421–6.PubMed

143.

Jensen M, Ratner C, Rudenko O, et al. Anxiolytic-like effects of increased ghrelin receptor signaling in the amygdala. Int J Neuropsychopharmacol. 2015;19:1–12.

144.

Frühbeck G, Kiortsis DN, Catalán V. Precision medicine: diagnosis and management of obesity. Lancet Diabetes Endocrinol [Internet]. 2018 [cited 2018 Aug 10];6:164–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28919063

145.

Schalla MA, Stengel A. Pharmacological modulation of ghrelin to induce weight loss: successes and challenges. Curr Diab Rep [Internet]. 2019 [cited 2019 Sep 15];19:102. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31506846

146.

Vlasova MA, Järvinen KHK. Cardiovascular effects of ghrelin antagonist in conscious rats. Regul Pept. 2009;156:72–6.PubMed

147.

Beheshti SAN. Local injection of d-lys-3-GHRP-6 in the rat amygdala, dentate gyrus or ventral tegmental area impairs memory consolidation. Neuropeptides. 2018;67:20–6.PubMed

148.

Puzio I, Piedra JLV, Kapica M, et al. Influence of intragastric administration of ghrelin receptor antagonist [D-LYS3]-GHRP-6 on bone tissue in rats. Bull Vet Inst Pulawy. 2011;55:501–5.

149.

Biotechnology C. Phase I/IIa clinical trial with obese individuals shows no effect of CYT009-GhrQb on weight loss. Cytos Biotechnol Press release. 7

150.

Denney WS, Sonnenberg GE, Carvajal-Gonzalez S, et al. Pharmacokinetics and pharmacodynamics of PF-05190457: the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects. Br J Clin Pharmacol. 83:326–38.

Titel: Revisiting the Ghrelin Changes Following Bariatric and Metabolic Surgery
verfasst von: Carlota Tuero
Victor Valenti
Fernando Rotellar
Manuel F. Landecho
Javier A. Cienfuegos
Gema Frühbeck
Publikationsdatum: 22.04.2020
Verlag: Springer US
Erschienen in: Obesity Surgery / Ausgabe 7/2020
Print ISSN: 0960-8923
Elektronische ISSN: 1708-0428
DOI: https://doi.org/10.1007/s11695-020-04601-5

Neu im Fachgebiet Chirurgie

23.04.2024 | Ablationstherapie | Nachrichten

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 | Appendizitis | Nachrichten

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 | Operationsvorbereitung | Nachrichten

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Ureterstriktur: Innovative OP-Technik bewährt sich

weitere anzeigen

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare

CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare

CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske

Dr. med. Benjamin Meyknecht

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare

CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2020

Are Noninvasive Methods Comparable to Liver Biopsy in Postoperative Patients After Roux-en-Y Gastric Bypass?

Improvement of Cardiac Function After Roux-en-Y Gastric Bypass in Morbidly Obese Patients Without Cardiac History Measured by Cardiac MRI

Bariatric Surgery in the Times of Corona

Evaluation of Liver Function Tests and Risk Score Assessment to Screen Patients for Significant Liver Disease Prior to Bariatric and Metabolic Surgery

Internal Hernia in the Times of COVID-19: to Laparoscope or Not to Laparoscope?

Single-port Laparoscopic Surgery for the Treatment of Severe Obesity: Review and Perspectives

Neu im Fachgebiet Chirurgie

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Hinter dieser Appendizitis steckte ein Erreger

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

Ureterstriktur: Innovative OP-Technik bewährt sich

Update Chirurgie

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

S2e-Leitlinie „Distale Radiusfraktur“

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“